EMA/PE/0000245628
Submitted by Anonymous (not verified) on 14 October 2026 - 9:39
EMA/PE/0000245628
EMA/PE/0000245862
Submitted by Anonymous (not verified) on 14 October 2026 - 9:39
EMA/PE/0000245862
Opinion/decision on a Paediatric investigation plan (PIP): Tevimbra, tislelizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts
Submitted by Anonymous (not verified) on 14 October 2026 - 9:35
Opinion/decision on a Paediatric investigation plan (PIP): Tevimbra, tislelizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: EMA/PE/0000235505
EMA/PE/0000234649
Submitted by Anonymous (not verified) on 14 October 2026 - 9:26
EMA/PE/0000234649
EMEA-003313-PIP02-23
Submitted by Anonymous (not verified) on 14 October 2026 - 8:51
EMEA-003313-PIP02-23
EMA/PE/0000223258
Submitted by Anonymous (not verified) on 14 October 2026 - 8:48
EMA/PE/0000223258
EMA/PE/0000223040
Submitted by Anonymous (not verified) on 14 October 2026 - 8:43
EMA/PE/0000223040
EMA/PE/0000183462
Submitted by Anonymous (not verified) on 14 October 2026 - 8:39
EMA/PE/0000183462
Human medicines European public assessment report (EPAR): Denosumab Ascend, denosumab, Date of authorisation: 28/08/2026, Status: Authorised
Submitted by Anonymous (not verified) on 14 October 2026 - 8:05
Human medicines European public assessment report (EPAR): Denosumab Ascend, denosumab, Date of authorisation: 28/08/2026, Status: Authorised
Qualification of novel methodologies for medicine development: CHMP qualification opinions
Submitted by Anonymous (not verified) on 13 October 2026 - 21:25
Qualification of novel methodologies for medicine development: CHMP qualification opinions